Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Systemic Lupus Erythematosus (SLE) as defined by meeting at least 4 of the 11 classification criteria of the American College of Rheumatology for the classification of Systemic Lupus Erythematosus, either sequentially or coincident. The 4 criteria need not be present at study entry~* Renal biopsy within 12 months prior to screening visit indicating active proliferative lupus glomerulonephritis (met ISN/RPS Class III or IV classification criteria \[2003\], excluding Class III \[C\], IV-S \[C\] and IV-G \[C\], or the World Health Organization Class III or IV classification criteria \[1982\], excluding Class IIIc, IVd). If the renal biopsy was performed \>3 months but ≤12 months prior to screening visit, at least 1 of the following 3 serologies (performed locally) must have been abnormal prior to screening visit: complement (C3 or C4) level below normal range OR anti-dsDNA \>upper limit of normal range.~* A stable serum creatinine ≤3 mg/dL~Exclusion Criteria:~* Subjects with a rise in serum creatinine of ≥1 mg/dL within 1 month prior to the screening visit~* Subjects with drug-induced SLE, as opposed to idiopathic SLE~* Subjects with severe, unstable and/or progressive Central nervous system (CNS) lupus~* Subjects with autoimmune disease other than SLE as their main diagnosis (e.g.; Rheumatoid arthritis (RA), Multiple Sclerosis \[MS\])~* Subjects who have received treatment with cyclophosphamide within 3 months of randomization (Day 1).~* Subjects who have received treatment with rituximab \< 6 months prior to the screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abatacept 30 mg/kg+Corticosteroids+MMF (Type: EXPERIMENTAL): Short-term Period
- Abatacept 10 mg/kg+Corticosteroids+MMF (Type: EXPERIMENTAL): Short-term Period
- Placebo+Corticosteroids+MMF (Type: EXPERIMENTAL): Short-term Period
- Abatacept 10mg/kg (Type: EXPERIMENTAL): Long-term Extension Period

Based on this trial design, predict the completion outcome and termination type (if applicable).